Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Research progress on epithelial mucosal barrier impairment contributing to chronic rhinosinusitis].

Created on 14 Sep 2026

Authors

Haosu Huang, Shouming Cao, Haiying Wu

Published in

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery. Volume 40. Issue 2. Pages 207-214.

Abstract

Chronic rhinosinusitis (CRS) is defined as sinonasal mucosal inflammation persisting for >12 weeks and presents with nasal congestion, rhinorrhea, facial pain/pressure and olfactory impairment. CRS markedly impairs quality of life and imposes a heavy economic burden on health-care systems. Recent research has shifted the pathophysiological paradigm from simple mechanical obstruction to an epithelial-barrier-centred model that emphasizes immune dysregulation and cellular aberrations. Its complex aetiology includes ciliary dysfunction; dysbiosis; cytokine imbalance; epithelial-mesenchymal transition (EMT); disruption of tight junctions by inflammatory mediators; environmental pollutants; allergens; cigarette smoke; and neuroendocrine disturbance-factors that are especially prominent in eosinophilic CRS with nasal polyps. Here we systematically review structural alterations and key molecular mechanisms driving epithelial barrier breakdown in CRS, providing a theoretical basis for future barrier-targeted therapies.

PMID:
41589379
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement